4'-epidoxorubicin + cyclophosphamide + procarbazine

This is a combination chemotherapy regimen consisting of three agents: - **4'-Epidoxorubicin (also known as epirubicin):** An anthracycline antibiotic structurally related to doxorubicin, differing by the configuration of the hydroxyl group at the 4' position. It acts primarily by intercalating into DNA and inhibiting nucleic acid synthesis and function, leading to cell cycle arrest and apoptosis. Epirubicin is less cardiotoxic than doxorubicin and has demonstrated antitumor activity in breast cancer, gastric cancer, lymphomas, ovarian cancer, soft tissue sarcomas, pancreatic cancer, and small-cell lung cancer[1][2][3][5]. - **Cyclophosphamide:** An alkylating agent that crosslinks DNA strands through its active metabolites (phosphoramide mustard), resulting in inhibition of DNA replication and cell death. - **Procarbazine:** An alkylating agent that inhibits protein synthesis by methylation of guanine residues in DNA; it also causes chromosomal damage. This combination would be expected to have broad-spectrum antineoplastic activity due to the complementary mechanisms of action. Each drug targets rapidly dividing cells via different pathways—DNA intercalation/inhibition (epirubicin), DNA crosslinking (cyclophosphamide), and methylation/chromosomal damage (procarbazine). Such regimens are typically used for various solid tumors or hematologic malignancies where multi-agent chemotherapy is indicated.

Other names

epirubicin + cyclophosphamide + procarbazine4'-epi-doxorubicin + cyclophosphamide + procarbazine